In a continuing saga of disapprovals, the FDA issued a Complete Response Letter (CRL) to Acadia Pharmaceuticals on its supplemental New Drug Application (sNDA) to expand the use of its Parkinson’s psychosis drug Nuplazid (pimavanserin) for treatment of Alzheimer’s disease psychosis (ADP).
Source: Drug Industry Daily